Zanubrutinib, another second-generation irreversible BTK inhibitor that is approved for R/R MZL patients, reduced Treg percent and CTLA-4 expression on Tregs in R/R CLL patients (111). This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.